Since OpenAI’s launch of ChatGPT Health, internet healthcare share prices have fluctuated significantly. In the period 15-29 January, PAGD and Medlive dropped 15.5% and 21.7% respectively, while Ant Group-backed Ali Health remained relatively stable. Many drug innovators retreated 5-10% after an early rally, but AI-driven Insilico surged 18.8%. With robust innovative pipelines, rapid R&D, and growing product offerings, China's healthcare sector is poised to become a key player in the global mark...
At the recent investor conference, global investors viewed Chinese healthcare companies with increasing interest and optimism. Impressed by their advanced R&D pipelines and swift R&D-to-market execution capabilities, investors recognised Chinese companies’ potential for innovation and growth, particularly as they presented an array of cuttingedge products ready for global markets. This positive perception reflects a growing confidence in China's healthcare sector as a key player on the internati...
In the first two weeks of Jan 26, Chinese healthcare stocks saw impressive share price increases. Fuelled by AI healthcare themes, Dian Diagnostics soared by 83.0%, while Ali Health and Medlive rose by 42.0% and 37.5% respectively. Expectations of strong revenue and earnings growths in 2026 also led to significant share price increases of 10-30% for drug innovators and CRDMO leaders. China’s healthcare sector will continue to outperform in 2026. Maintain OVERWEIGHT.
Greater China Economics | Money Supply December’s monetary data was mixed. M1 growth slowed further to 3.8% yoy, slightly below expectations, while M2 growth improved to 8.5% yoy on stronger time deposits growth. On a positive note, new bank loans rebounded to Rmb0.91t, mainly driven by corporate and government borrowing, and new TSF also beat forecasts. However, outstanding bank loan growth stayed at a year-low of 6.4% yoy and TSF growth eased to 8.3% yoy, underscoring still-fragile credit ...
The sector experienced a fruitful year of innovation in 2025, and we expect globalisation and improving operating efficiency to continue to drive rapid earnings growth for drug innovators and CRO leaders from 2026 onwards. Seeing strong online demand, internet healthcare players are likely to sustain solid revenue and earnings expansion in 2026. We also anticipate that domestic medical device manufacturers will experience a gradual sales growth recovery, fuelled by technological advancements and...
Greater China Sector Update | Healthcare The sector experienced a fruitful year of innovation in 2025, and we expect globalisation and improving operating efficiency to continue to drive rapid earnings growth for drug innovators and CRO leaders from 2026 onwards. Seeing strong online demand, internet healthcare players are likely to sustain solid revenue and earnings expansion in 2026. We also anticipate that domestic medical device manufacturers will experience a gradual sales growth recove...
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
China healthcare stocks were relatively weak during the first two weeks of Dec 25 as investors took profits, particularly for internet healthcare and drug innovator names. Fundamentals remain solid, supported by the new commercial insurance policy, lower costs of capital, and robust pipelines. Despite rising competition in areas like generics, GLP-1 drugs and surgical robots, companies continue to advance towards sustainable growth. Maintain OVERWEIGHT. Our top picks are BeOne Medicines, Hansoh ...
Most Chinese healthcare stock prices fell along with the weak Hang Seng Index in the past two weeks. The share prices of leading drug innovators, however, have remained relatively stable. We expect drug innovators to continue to outperform, supported by possible further lowering of interest rates, increasing innovative product launches, and globalisation efforts. Meanwhile, geopolitical risks and GPO and other policy uncertainties will remain as key risks amid the recovery for CROs, medical serv...
A director at AstraZeneca sold 7,500 shares at 177.269USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
After a significant pullback over the past two months, most Chinese healthcare stock prices have stabilised and are beginning to regain strength. Major biopharmaceuticals are leading the recovery supported by their strong 9M25 results. We expect the momentum to continue, given improving fundamentals across sub-segments. Moreover, the lower cost of capital, continuous innovation and globalisation efforts, and supportive policies eg new Commercial Health Insurance Innovative Drug List, will suppor...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.